Compare National Beverage Corp. (FIZZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Travere Therapeutics Inc. Common Stock — how do they compare? National Beverage Corp. trades at $33.54 (market cap $3.08B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 32 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FIZZ | TVTX | |
|---|---|---|
Market Cap | $3.08B | $4.88B |
Volume | 604,078 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $67.52 |
52-Week Low | $29.20 | $26.79 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $3.04B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $33.54, up 4.32% with a bullish technical signal. The stock shows strong profitability with 14.81% net margins and 40.13% ROE, though recent quarters have seen earnings misses. Cash flow turned negative in 2025 due to significant financing outflows. Technical indicators suggest bullish momentum despite overbought RSI readings near 73.
FIZZ faces mixed sentiment with 50% analyst sell ratings but strong institutional interest. Revenue growth remains stagnant while margin pressure from input costs presents headwinds. The current valuation at 17.7x P/E appears reasonable given profitability, but execution risks and competitive pressures warrant caution for investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
